Abstract

Regulatory T cells (Treg cells) have a critical role in the maintenance of immunological self-tolerance. Here we show that treatment of naive human or mouse T cells with IL-35 induced a regulatory population, which we call 'iTR35 cells', that mediated suppression via IL-35 but not via the inhibitory cytokines IL-10 or transforming growth factor-β (TGF-β). We found that iTR35 cells did not express or require the transcription factor Foxp3, and were strongly suppressive and stable in vivo. Treg cells induced the generation of iTR35 cells in an IL-35- and IL-10-dependent manner in vitro and induced their generation in vivo under inflammatory conditions in intestines infected with Trichuris muris and within the tumor microenvironment (B16 melanoma and MC38 colorectal adenocarcinoma), where they contributed to the regulatory milieu. Thus, iTR35 cells constitute a key mediator of infectious tolerance and contribute to Treg cell–mediated tumor progression. Furthermore, iTR35 cells generated ex vivo might have therapeutic utility.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Accessions

Gene Expression Omnibus

References

  1. 1.

    , , & A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat. Immunol. 6, 1142–1151 (2005).

  2. 2.

    et al. Foxp3-dependent programme of regulatory T-cell differentiation. Nature 445, 771–775 (2007).

  3. 3.

    , & Control of regulatory T cell development by the transcription factor Foxp3. Science 299, 1057–1061 (2003).

  4. 4.

    , , & Infectious tolerance and the long-term acceptance of transplanted tissue. Immunol. Rev. 212, 301–313 (2006).

  5. 5.

    & Mitigation of experimental allergic encephalomyelitis by TGF-B induced Foxp3+ regulatory T lymphocytes through the induction of anergy and infectious tolerance. J. Immunol. 180, 2830–2838 (2008).

  6. 6.

    , & Impaired IL-10-dependent induction of tolerogenic dendritic cells by CD4+CD25hiCD127lo/− natural regulatory T cells in human allergic asthma. Am. J. Respir. Crit. Care Med. 180, 823–833 (2009).

  7. 7.

    & Natural versus adaptive regulatory T cells. Nat. Rev. Immunol. 3, 253–257 (2003).

  8. 8.

    From vanilla to 28 flavors: multiple varieties of T regulatory cells. Immunity 25, 195–201 (2006).

  9. 9.

    , , , & The development and function of regulatory T cells. Cell. Mol. Life. Sci. 6, 2603–2622 (2009).

  10. 10.

    et al. Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol. Rev. 212, 28–50 (2006).

  11. 11.

    Therapeutic use of T regulatory cells. Curr. Opin. Rheumatol. 19, 252–258 (2007).

  12. 12.

    et al. Conversion of peripheral CD4+CD25 naive T cells to CD4+CD25+ regulatory T cells by TGF-β induction of transcription factor Foxp3. J. Exp. Med. 198, 1875–1886 (2003).

  13. 13.

    et al. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 389, 737–742 (1997).

  14. 14.

    et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 450, 566–569 (2007).

  15. 15.

    Regulatory T cells: key controllers of immunologic self-tolerance. Cell 101, 455–458 (2000).

  16. 16.

    et al. TGF-β-induced Foxp3+ regulatory T cells rescue scurfy mice. Eur. J. Immunol. 38, 1814–1821 (2008).

  17. 17.

    et al. In vivo Treg suppression assays. in Regulatory T cells: Methods and Protocols (Springer-Humana, New York, in the press).

  18. 18.

    , , & On the ontogeny and physiology of regulatory T cells. Immunol. Rev. 182, 5–17 (2001).

  19. 19.

    et al. Lymphocyte activation gene-3 (CD223) regulates the size of the expanding T cell population following antigen activation in vivo. J. Immunol. 172, 5450–5455 (2004).

  20. 20.

    , , & Cutting edge: CD4+CD25+ regulatory T cells suppress antigen-specific autoreactive immune responses and central nervous system inflammation during active experimental autoimmune encephalomyelitis. J. Immunol. 169, 4712–4716 (2002).

  21. 21.

    , & Natural recovery and protection from autoimmune encephalomyelitis: contribution of CD4+CD25+ regulatory cells within the central nervous system. J. Immunol. 175, 3025–3032 (2005).

  22. 22.

    et al. Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J. Exp. Med. 200, 771–782 (2004).

  23. 23.

    , , , & Induction of postsurgical tumor immunity and T-cell memory by a poorly immunogenic tumor. Cancer Res. 67, 6468–6476 (2007).

  24. 24.

    , & Regulatory T cells suppress systemic and mucosal immune activation to control intestinal inflammation. Immunol. Rev. 212, 256–271 (2006).

  25. 25.

    et al. Infectious tolerance: human CD25+ regulatory T cells convey suppressor activity to conventional CD4+ T helper cells. J. Exp. Med. 196, 255–260 (2002).

  26. 26.

    , , & Regulatory T cells and their role in rheumatic diseases: a potential target for novel therapeutic development. Pediatr Rheumatol Online J 6, 20 (2008).

  27. 27.

    Tolerance can be infectious. Nat. Immunol. 9, 1001–1003 (2008).

  28. 28.

    , , & Regulatory T cell suppression is potentiated by target T cells in a cell contact, IL-35- and IL-10-dependent manner. J. Immunol. 182, 6121–6128 (2009).

  29. 29.

    , , & Regulatory T cells: a role in the control of helminth-driven intestinal pathology and worm survival. J. Immunol. 182, 2340–2348 (2009).

  30. 30.

    et al. T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood 113, 6392–6402 (2009).

  31. 31.

    et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J. Immunol. 169, 2756–2761 (2002).

  32. 32.

    & Generation and decay of the immune response to a progressive fibrosarcoma. I. Ly-1+2 suppressor T cells down-regulate the generation of Ly-12+ effector T cells. J. Exp. Med. 159, 1295–1311 (1984).

  33. 33.

    et al. Breast cancer lung metastasis requires expression of chemokine receptor CCR4 and regulatory T cells. Cancer Res. 69, 5996–6004 (2009).

  34. 34.

    Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat. Rev. Cancer 5, 263–274 (2005).

  35. 35.

    Regulatory T cells, tumour immunity and immunotherapy. Nat. Rev. Immunol. 6, 295–307 (2006).

  36. 36.

    et al. Combination therapy with anti-CTL antigen-4 and anti-4–1BB antibodies enhances cancer immunity and reduces autoimmunity. Cancer Res. 66, 7276–7284 (2006).

  37. 37.

    , , , & Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J. Exp. Med. 206, 1717–1725 (2009).

  38. 38.

    et al. In vitro generation of interleukin 10-producing regulatory CD4+ T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines. J. Exp. Med. 195, 603–616 (2002).

  39. 39.

    et al. Activation of human CD4+ cells with CD3 and CD46 induces a T-regulatory cell 1 phenotype. Nature 421, 388–392 (2003).

  40. 40.

    et al. CD4+ FoxP3+ regulatory T cells confer infectious tolerance in a TGF-β-dependent manner. J. Exp. Med. 205, 1975–1981 (2008).

  41. 41.

    , , , & Inducible reprogramming of human T cells into Treg cells by a conditionally active form of FOXP3. Eur. J. Immunol. 38, 3282–3289 (2008).

  42. 42.

    , , , & Human CD4+ CD25+ Foxp3+ regulatory T cells do not constitutively express IL-35. J. Immunol. 181, 6898–6905 (2008).

  43. 43.

    et al. Regulatory T cells generated ex vivo as an approach for the therapy of autoimmune disease. Semin. Immunol. 16, 135–143 (2004).

  44. 44.

    Models of T cell anergy: is there a common molecular mechanism? J. Exp. Med. 184, 1–8 (1996).

  45. 45.

    & Profound enhancement of T cell activation mediated by the interaction between the TCR and the D3 domain of CD4. J. Immunol. 162, 1431–1439 (1999).

  46. 46.

    et al. Role of LAG-3 in regulatory T cells. Immunity 21, 503–513 (2004).

  47. 47.

    & Approximate variance-stabilizing transformations for gene-expression microarray data. Bioinformatics 19, 966–972 (2003).

  48. 48.

    et al. The transcription factor T-bet controls regulatory T cell homeostasis and function during type 1 inflammation. Nat. Immunol. 10, 595–602 (2009).

  49. 49.

    , & Cutting edge: cure of colitis by CD4+CD25+ regulatory T cells. J. Immunol. 170, 3939–3943 (2003).

  50. 50.

    et al. The IL-27 receptor (WSX-1) is an inhibitor of innate and adaptive elements of type 2 immunity. J. Immunol. 173, 5626–5634 (2004).

Download references

Acknowledgements

We thank R. Blumberg and T. Kuo (Brigham and Women's Hospital) for Ebi3−/− mice; A. Rudensky (Memorial Sloan-Kettering Cancer Center) for Foxp3gfp mice; J. Ihle (St. Jude Children's Research Hospital; with permission from A. Rudensky) for Foxp3−/− mice; T. Geiger (St. Jude Children's Research Hospital) for Il10−/− mice; B. Triplett, D. Regan, M. Howard and M. McKenna (St. Louis Cord Blood Bank) for cord blood samples; D. Campana (St. Jude Children's Research Hospital) for the proprietary permeabilization buffer; A. Korman and M. Selby (Medarex–Bristol Myers Squibb) for MC38 colorectal adenocarcinoma cells; and S. Burns, H. Chi, R. Cross, K. Forbes, D. Green, G. Lennon, L. Jones, A. Krause, T. Moore, S. Morgan, A. Szymczak-Workman and K. Vignali for discussions and assistance. Supported by the National Institutes of Health (R01 AI39480 to D.A.A.V.; R01 AI61570 and R01 AI74878 to D.A.; and F32 AI072816 to L.W.C.), the Australian National Health and Medical Research Council Overseas Biomedical Fellowship Program (P.R.G.), the National Cancer Institute Comprehensive Cancer Center (CA21765 subaward to D.A.A.V.) and the American Lebanese Syrian Associated Charities (D.A.A.V.).

Author information

Author notes

    • Abigail L Henderson

    Present address: Department of Research, Des Moines University, Des Moines, Iowa, USA.

Affiliations

  1. Department of Immunology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.

    • Lauren W Collison
    • , Vandana Chaturvedi
    • , Abigail L Henderson
    • , Cliff Guy
    • , Jaishree Bankoti
    • , Karen Forbes
    • , Creg J Workman
    • , Scott A Brown
    •  & Dario A A Vignali
  2. Department of Microbiology and Department of Pathobiology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

    • Paul R Giacomin
    •  & David Artis
  3. Department of Bioinformatics, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.

    • David Finkelstein
  4. Department of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.

    • Jerold E Rehg
  5. Shenandoah Biotechnology, Monroe, Ohio, USA.

    • Michael L Jones
  6. Department of Antibody Applications, R&D Systems, Minneapolis, Minnesota, USA.

    • Hsiao-Tzu Ni
  7. Department of Microbiology and Immunology, Dartmouth Medical School, Lebanon, New Hampshire, USA.

    • Mary Jo Turk

Authors

  1. Search for Lauren W Collison in:

  2. Search for Vandana Chaturvedi in:

  3. Search for Abigail L Henderson in:

  4. Search for Paul R Giacomin in:

  5. Search for Cliff Guy in:

  6. Search for Jaishree Bankoti in:

  7. Search for David Finkelstein in:

  8. Search for Karen Forbes in:

  9. Search for Creg J Workman in:

  10. Search for Scott A Brown in:

  11. Search for Jerold E Rehg in:

  12. Search for Michael L Jones in:

  13. Search for Hsiao-Tzu Ni in:

  14. Search for David Artis in:

  15. Search for Mary Jo Turk in:

  16. Search for Dario A A Vignali in:

Contributions

L.W.C. designed (with help from D.A.A.V.) and did all mouse experiments, analyzed data and wrote the manuscript; V.C. did human experiments; A.L.H. (with L.W.C.) did the B16 tumor experiments; J.B. did the MC38 tumor experiments; P.R.G. infected mice with T. muris; C.G. did confocal microscopy; D.F. analyzed Affymetrix data; K.F. and S.A.B (with C.J.W.) generated and screened monoclonal antibodies to IL-35; C.J.W. coordinated the development of monoclonal anti-IL-35 and aided in figure preparation; M.L.J. generated and purified mouse Ebi3 protein for immunization and the development of monoclonal antibodies; H.-T.N. provided reagents and information; J.E.R. created and did histological analyses of Foxp3−/− mice; D.A. designed T. muris experiments and provided input on their interpretation; M.J.T. provided training for the B16 tumor model and provided input to research design and interpretation; and D.A.A.V. conceived of the research, directed the study and edited the manuscript.

Competing interests

D.A.A.V. and L.W.C. have submitted a patent based on this work that is now pending. Also, D.A.A.V., L.W.C. and C.J.W. have also submitted a patent on IL-35 and are entitled to a share in net income generated from licensing of these patent rights for commercial development. M.L.J. is employed by Shenandoah Biotechnology and H.-T.N. is employed by R&D Systems.

Corresponding author

Correspondence to Dario A A Vignali.

Supplementary information

PDF files

  1. 1.

    Supplementary Text and Figures

    Supplementary Figures 1–18

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/ni.1952

Further reading